SCHEMBL6959482

SCHEMBL6959482

CC1(C)CC(=O)Oc2ccc(N)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 1/20 0.44
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
FTO Q9C0B1 1/20 0.35
MAPT P10636 6/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
GAA P10253 3/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
GFER P55789 1/20 0.33
MITF O75030 1/20 0.33
MAPK1 P28482 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CA9 Q16790 1/20 0.33
CYP19A1 P11511 2/20 0.33
BACE1 P56817 3/20 0.32
LMNA P02545 2/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12440421 0.81 KDM4E (0.49) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL9748001 0.80 MAPT (0.46) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL4478866 0.80 ALDH1A1 (0.44) KDM4EALDH1A1HPGDKMT2AMAPT
SCHEMBL1850175 0.80 KDM4E (0.44) KDM4EALDH1A1HPGDBACE1CTSD
SCHEMBL5781258 0.78 ALDH1A1 (0.42) KDM4EALDH1A1HPGDMAPTNPC1
SCHEMBL9024853 0.76 KDM4E (0.41) KDM4EALDH1A1HPGDBACE1
SCHEMBL6954373 0.76 AKR1B1 (0.42) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL1404926 0.75 ALDH1A1 (0.49) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL9024103 0.73 KDM4E (0.38) KDM4EALDH1A1HPGD
SCHEMBL6958887 0.73 ALDH1A1 (0.41) KDM4EALDH1A1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030130342-A1 Glycoprotein llb/llla antagonists FISHER MATTHEW J (US) 2003-07-10 US disclosed
EP-0804431-B9 GLYCOPROTEIN IIb/IIIa ANTAGONISTS LILLY CO ELI (US) 2003-01-02 EP disclosed
US-6448269-B1 SUCH AS 6-(N-(4-(AMINOIMINOMETHYL)BENZOYL)AMINO)-3,4-DIHYDRO-4,4-DIMETHYL-2H-1 -BENZOPYRAN-2-YL)ACETIC ACID; INHIBITING PLATELET AGGREGATION OR FIBRINOGEN BINDING OR PREVENTING THROMBOSIS ELI LILLY AND COMPANY 2002-09-10 US disclosed
EP-0804431-B1 GLYCOPROTEIN IIb/IIIa ANTAGONISTS LILLY CO ELI (US) 2002-07-24 EP disclosed
US-6020362-A ANTICOAGULANTS ELI LILLY AND COMPANY (US) 2000-02-01 US disclosed
EP-0804431-A4 GLYCOPROTEIN IIb/IIIa ANTAGONISTS LILLY CO ELI (US) 1998-04-29 EP disclosed
US-5731324-A Glycoprotein IIb/IIIa antagonists ELI LILLY AND COMPANY (US) 1998-03-24 US disclosed
EP-0804431-A1 GLYCOPROTEIN IIb/IIIa ANTAGONISTS ELI LILLY AND COMPANY (US) 1997-11-05 EP disclosed
WO-1996022288-A1 GLYCOPROTEIN IIb/IIIa ANTAGONISTS ELI LILLY AND COMPANY (US) 1996-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130342-A1 Glycoprotein llb/llla antagonists SELL, SELPLG, LY96 KDM4E 4764/4885ALDH1A1 1693/4885HPGD 1023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.